Edition:
United Kingdom

Medigene AG (MDG1k.DE)

MDG1k.DE on Xetra

12.48EUR
4:35pm BST
Change (% chg)

€-0.21 (-1.65%)
Prev Close
€12.69
Open
€12.71
Day's High
€12.80
Day's Low
€12.43
Volume
72,361
Avg. Vol
209,376
52-wk High
€19.42
52-wk Low
€8.53

Select another date:

Mon, May 14 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

BRIEF-Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​

* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011

BRIEF-Medigene Receives Approvals For First Clinical Trial With MDG1011

* SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011

BRIEF-Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR

* MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: